BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Northwest Biotherapeutics, Inc. 

21720 23rd Drive SE, Suite 100

Bothell  Washington  98021  U.S.A.
Phone: 425-608-3000-or-877-606-9246-Toll-Free Fax: 425-608-3026


SEARCH JOBS

View Clinical Trials from BioPharm Insight



Industry
Services


Collaborations

Cytogen Corporation  Development of ex vivo prostate cancer immunotherapy





 Company News
Northwest Biotherapeutics (NWBO) Reports $35M In Financing 11/20/2014 5:58:07 AM
Northwest Biotherapeutics (NWBO) Release: DCVAX®-L Hospital Exemption Program Now Under Way In Germany 10/14/2014 12:50:20 PM
Northwest Biotherapeutics (NWBO) Secures $11.5 Million Financing 10/7/2014 7:11:59 AM
Experimental Northwest Biotherapeutics (NWBO) Drug Gets First Slot Under UK Early Access Scheme 9/16/2014 6:00:01 AM
Northwest Biotherapeutics (NWBO) CEO To Present At SMI's 3rd Annual Cancer Vaccines Conference In London 9/15/2014 9:30:39 AM
Northwest Biotherapeutics (NWBO) To Present Updates At Rodman & Renshaw 16th Annual Global Investment Conference 9/8/2014 9:00:16 AM
Northwest Biotherapeutics (NWBO) Completes The Closing Of Its $17.5 Million Convertible Note Offering 8/19/2014 12:57:39 PM
Northwest Biotherapeutics (NWBO) Announces Pricing Of $17.5 Million Offering Of Convertible Notes 8/14/2014 10:47:33 AM
Northwest Biotherapeutics (NWBO) Corrects Ongoing False Claims, Phase 3 Dcvax®-L Trial Is Alive And Well 8/13/2014 7:47:40 AM
Northwest Biotherapeutics (NWBO) Obtains Approvals For Enhancements Of Phase 3 Trial Of Dcvax®-L For Gbm Brain Cancer 8/11/2014 7:46:45 AM
12345678910...